Immuno-PET for Clinical Theranostic Approaches - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles International Journal of Molecular Sciences Year : 2016

Immuno-PET for Clinical Theranostic Approaches


Recent advances in molecular characterization of tumors have allowed identification of new molecular targets on tumor cells or biomarkers. In medical practice, the identification of these biomarkers slowly but surely becomes a prerequisite before any treatment decision, leading to the concept of personalized medicine. Immuno-positron emission tomography (PET) fits perfectly with this approach. Indeed, monoclonal antibodies (mAbs) labelled with radionuclides represent promising probes for theranostic approaches, offering a non-invasive solution to assess in vivo target expression and distribution. Immuno-PET can potentially provide useful information for patient risk stratification, diagnosis, selection of targeted therapies, evaluation of response to therapy, prediction of adverse effects or for titrating doses for radioimmunotherapy. This paper reviews some aspects and recent developments in labelling methods, biological targets, and clinical data of some novel PET radiopharmaceuticals.


Fichier principal
Vignette du fichier
BaillyIntJMolSciEq13.pdf (1.01 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-01636873 , version 1 (17-11-2017)



Clément Bailly, Pierre-François Cléry, Alain Faivre-Chauvet, Mickael Bourgeois, François Guérard, et al.. Immuno-PET for Clinical Theranostic Approaches. International Journal of Molecular Sciences, 2016, 18 (1), Epub ahead of print. ⟨10.3390/ijms18010057⟩. ⟨inserm-01636873⟩
189 View
120 Download



Gmail Facebook Twitter LinkedIn More